Soleno Therapeutics (SLNO) Non-Current Assets (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Non-Current Assets data on file, last reported at $282.0 million in Q1 2026.

• On a quarterly basis, Non-Current Assets rose 2973.03% year-over-year to $282.0 million in Q1 2026; TTM through Mar 2026 was $570.6 million, a 370.02% increase from a year earlier, with the FY2025 full-year figure at $208.0 million, up 460.95% from the prior year.
• Non-Current Assets for Q1 2026 stood at $282.0 million, up from $208.0 million in the prior quarter.
• Over the last five years, Non-Current Assets for SLNO reached as high as $282.0 million in Q1 2026 and fell as low as $9.2 million in Q1 2025.
• Historically, Non-Current Assets has averaged $46.9 million across 5 years, with a median of $12.6 million in 2022.
• Across the five-year window, Non-Current Assets plunged 57.64% in 2025 and soared 2973.03% in 2026, its largest moves.
• Year by year, Non-Current Assets stood at $10.8 million in 2022, then decreased by 13.98% to $9.3 million in 2023, then soared by 297.33% to $37.1 million in 2024, then surged by 460.95% to $208.0 million in 2025, then jumped by 35.57% to $282.0 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $282.0 million in Q1 2026, $208.0 million in Q4 2025, and $65.0 million in Q3 2025.